Latanoprost acid

Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor[1]. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes[2].

Product Specifications

CAS Number

[41639-83-2]

Product Name Alternative

UT-15

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/latanoprost-acid.html

Purity

99.62

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@@H]([C@H]([C@@H](C1)O)CC[C@H](CCC2=CC=CC=C2)O)C/C=C\CCCC(O)=O

Molecular Formula

C23H34O5

Molecular Weight

390.51

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Weinreb RN, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S53-64.|[2]Xu X, et al. The prevention of latanoprost on osteoclastgenesis in vitro and lipopolysaccharide-induced murine calvaria osteolysis in vivo. J Cell Biochem. 2018 Jun;119 (6) :4680-4691.